Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era

Altynay Shigayeva; Brenda L. Coleman; Alyssa Golden; Irene Martin; George Zhanel; Heather Adam; Wayne L. Gold; Christopher Kandel; Kevin Katz; J. Kapala; Reena Lovinsky; Matthew P. Muller; Krystyna Ostrowska; Neil Rau; Daniel Ricciuto; David Richardson; Christie Vermeiren; Amna Faheem; Lubna Farooqi; Karen A. Green; Kazi Hassan; Maxime Lefebvre; Angel Xinliu Li; Nadia Malik; Sarah Nayani; Paolo Pelosi; Agron Plevneshi; Asfia Sultana; Tamara Vikulova; Zoë Zhong; Allison McGeer

doi:10.1016/j.vaccine.2026.128351

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

In our population, pneumococcal antimicrobial resistance has remained relatively stable, but changes differ by antibiotic class. Implementation of vaccination programs with PCV20 or PCV21 should reduce AMR by disease prevention.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Shigayeva et al. (2026) studied this question.

synapsesocial.com/papers/69ad1199e7e9681137aa84a3 https://doi.org/10.1016/j.vaccine.2026.128351

View Full Paper

Ask AI

Bookmark

Share

Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era

Ask about this paper

Abstract

Discussion

Cite This Study

Prevalence of and risk factors for antimicrobial resistance in pneumococcal disease in southern Ontario during the PCV13 era

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading